vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PEGASYSTEMS INC (PEGA). Click either name above to swap in a different company.
PEGASYSTEMS INC is the larger business by last-quarter revenue ($430.0M vs $281.3M, roughly 1.5× Guardant Health, Inc.). PEGASYSTEMS INC runs the higher net margin — 7.6% vs -45.7%, a 53.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -9.6%). PEGASYSTEMS INC produced more free cash flow last quarter ($206.5M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 10.7%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Pegasystems Inc. (Pega) is a global software company based in Waltham, Massachusetts, in the United States, and founded in 1983. The company has been publicly traded since 1996 as PEGA (NASDAQ). Pega is a low-code platform for workflow automation and generative AI-powered decision-making for businesses.
GH vs PEGA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $430.0M |
| Net Profit | $-128.5M | $32.8M |
| Gross Margin | 64.6% | 75.2% |
| Operating Margin | -43.0% | 8.6% |
| Net Margin | -45.7% | 7.6% |
| Revenue YoY | 39.4% | -9.6% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $430.0M | ||
| Q4 25 | $281.3M | $504.3M | ||
| Q3 25 | $265.2M | $381.4M | ||
| Q2 25 | $232.1M | $384.5M | ||
| Q1 25 | $203.5M | $475.6M | ||
| Q4 24 | $201.8M | $490.8M | ||
| Q3 24 | $191.5M | $325.1M | ||
| Q2 24 | $177.2M | $351.2M |
| Q1 26 | — | $32.8M | ||
| Q4 25 | $-128.5M | $234.6M | ||
| Q3 25 | $-92.7M | $43.4M | ||
| Q2 25 | $-99.9M | $30.1M | ||
| Q1 25 | $-95.2M | $85.4M | ||
| Q4 24 | $-111.0M | $119.1M | ||
| Q3 24 | $-107.8M | $-14.4M | ||
| Q2 24 | $-102.6M | $6.6M |
| Q1 26 | — | 75.2% | ||
| Q4 25 | 64.6% | 79.5% | ||
| Q3 25 | 64.7% | 72.2% | ||
| Q2 25 | 65.0% | 71.5% | ||
| Q1 25 | 63.3% | 78.5% | ||
| Q4 24 | 61.6% | 79.1% | ||
| Q3 24 | 61.1% | 70.2% | ||
| Q2 24 | 59.1% | 72.4% |
| Q1 26 | — | 8.6% | ||
| Q4 25 | -43.0% | 20.7% | ||
| Q3 25 | -37.3% | 3.8% | ||
| Q2 25 | -45.9% | 4.5% | ||
| Q1 25 | -54.6% | 26.7% | ||
| Q4 24 | -62.4% | 29.1% | ||
| Q3 24 | -61.3% | -3.6% | ||
| Q2 24 | -56.8% | 3.7% |
| Q1 26 | — | 7.6% | ||
| Q4 25 | -45.7% | 46.5% | ||
| Q3 25 | -35.0% | 11.4% | ||
| Q2 25 | -43.0% | 7.8% | ||
| Q1 25 | -46.8% | 18.0% | ||
| Q4 24 | -55.0% | 24.3% | ||
| Q3 24 | -56.3% | -4.4% | ||
| Q2 24 | -57.9% | 1.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $-1.01 | $0.81 | ||
| Q3 25 | $-0.74 | $0.24 | ||
| Q2 25 | $-0.80 | $0.17 | ||
| Q1 25 | $-0.77 | $0.91 | ||
| Q4 24 | $-0.90 | $1.35 | ||
| Q3 24 | $-0.88 | $-0.17 | ||
| Q2 24 | $-0.84 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $270.0M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $705.9M |
| Total Assets | $2.0B | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $270.0M | ||
| Q4 25 | $378.2M | $425.8M | ||
| Q3 25 | $580.0M | $351.4M | ||
| Q2 25 | $629.1M | $411.6M | ||
| Q1 25 | $698.6M | $371.7M | ||
| Q4 24 | $525.5M | $740.0M | ||
| Q3 24 | $585.0M | $703.0M | ||
| Q2 24 | $933.7M | $665.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $705.9M | ||
| Q4 25 | $-99.3M | $787.4M | ||
| Q3 25 | $-354.5M | $596.8M | ||
| Q2 25 | $-305.5M | $624.5M | ||
| Q1 25 | $-250.8M | $611.3M | ||
| Q4 24 | $-139.6M | $585.5M | ||
| Q3 24 | $-60.1M | $473.0M | ||
| Q2 24 | $-1.6M | $435.4M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $2.0B | $1.6B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.5B | $1.8B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | $206.5M |
| FCF MarginFCF / Revenue | -19.3% | 48.0% |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $494.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $158.4M | ||
| Q3 25 | $-35.4M | $56.3M | ||
| Q2 25 | $-60.3M | $86.3M | ||
| Q1 25 | $-62.7M | $204.2M | ||
| Q4 24 | $-64.5M | $95.2M | ||
| Q3 24 | $-51.1M | $30.5M | ||
| Q2 24 | $-94.0M | $40.1M |
| Q1 26 | — | $206.5M | ||
| Q4 25 | $-54.2M | $152.4M | ||
| Q3 25 | $-45.8M | $51.8M | ||
| Q2 25 | $-65.9M | $84.1M | ||
| Q1 25 | $-67.1M | $202.3M | ||
| Q4 24 | $-83.4M | $92.4M | ||
| Q3 24 | $-55.3M | $27.4M | ||
| Q2 24 | $-99.1M | $38.8M |
| Q1 26 | — | 48.0% | ||
| Q4 25 | -19.3% | 30.2% | ||
| Q3 25 | -17.3% | 13.6% | ||
| Q2 25 | -28.4% | 21.9% | ||
| Q1 25 | -33.0% | 42.5% | ||
| Q4 24 | -41.3% | 18.8% | ||
| Q3 24 | -28.9% | 8.4% | ||
| Q2 24 | -55.9% | 11.1% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 1.2% | ||
| Q3 25 | 3.9% | 1.2% | ||
| Q2 25 | 2.4% | 0.6% | ||
| Q1 25 | 2.2% | 0.4% | ||
| Q4 24 | 9.4% | 0.6% | ||
| Q3 24 | 2.2% | 0.9% | ||
| Q2 24 | 2.9% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.68× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 2.87× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | — | 0.80× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 6.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PEGA
| Pega Cloud | $205.0M | 48% |
| Subscription license | $94.9M | 22% |
| Maintenance | $75.3M | 18% |
| Consulting | $54.8M | 13% |
